{"id":1831,"date":"2026-02-06T21:24:14","date_gmt":"2026-02-06T21:24:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/1831\/"},"modified":"2026-02-06T21:24:14","modified_gmt":"2026-02-06T21:24:14","slug":"why-shares-of-novo-nordisk-stock-collapsed-this-week-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/1831\/","title":{"rendered":"Why Shares of Novo Nordisk Stock Collapsed This Week"},"content":{"rendered":"\n

Shares of Novo Nordisk (NYSE: NVO) were down over 20% this week as of this writing on Friday, February 6th, at 11:00 AM EST, according to data from S&P Global Market Intelligence<\/a>. The famed drugmaker<\/a> has struggled over the last two years due to heavy competition and pricing pressure for weight-loss drugs. It is also trying to deal with aggressive competition from Hims & Hers.<\/p>\n

Right now, Novo Nordisk stock is down 68% from all-time highs set in early 2024. Here’s why it was falling again this week, and whether it is a buy today.<\/p>\n

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor.\u00a0See the stocks \u00bb<\/a><\/p>\n

Novo Nordisk reported earnings<\/a> earlier this week, on February 3rd. Its financials looked solid, with revenue growing 10% year over year in constant currency in 2025, despite heavy pressure from other weight-loss drugmakers such as Eli Lilly.<\/p>\n

However, investors were spooked by the weak 2026 guidance, which calls for a 5%-13% decline in sales and earnings compared to 2025. There is mounting competition for weight-loss drugs, including the new TrumpRx website, which offers discounted versions of these drugs, such as the company’s Wegovy product. Even though the company had its oral weight-loss pill approved by the Food and Drug Administration (FDA) and should see volume increases, declining prices will be a hit to sales and earnings in 2026.<\/p>\n

What’s more, in some countries, generic versions of weight-loss drugs are already on the market, which management expects will eat into sales. Lastly, to add even more chaos to the situation, telehealth marketplaces Hims & Hers launched a knockoff of Wegovy and began selling it for just $49 a month. While it is highly likely the FDA will quickly whip Hims & Hers into shape, more uncertainty is never something that Wall Street is looking for.<\/p>\n

\"Three Image source: Novo Nordisk. <\/p>\n

This is the worst price drawdown in Novo Nordisk’s history, going back to 1990. Despite this, the stock has produced a cumulative total return of over 30,000% for shareholders since 1990, making it one of the best-performing stocks of the last few decades.<\/p>\n

Novo Nordisk is a methodical business, banking on steady innovations over the last 100 years when it first invented Insulin. Weight-loss drugs are its new blockbuster, facing competition today but still poised to be a huge market over the next few decades.<\/p>\n

At a price-to-earnings ratio (P\/E) of 13, investors are heavily discounting the likelihood that Novo Nordisk will maintain its market share in weight-loss drugs, and they completely discount any future drug innovations in its pipeline. If you like this business, now may be a good time to buy the dip on Novo Nordisk stock.<\/p>\n

Before you buy stock in Novo Nordisk, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $436,126!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,053,659!*<\/p>\n

Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 885% \u2014 a market-crushing outperformance compared to 192% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n

See the 10 stocks \u00bb<\/a><\/p>\n

*Stock Advisor returns as of February 6, 2026. <\/p>\n

Brett Schafer<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n

Why Shares of Novo Nordisk Stock Collapsed This Week<\/a> was originally published by The Motley Fool<\/p>\n","protected":false},"excerpt":{"rendered":"Shares of Novo Nordisk (NYSE: NVO) were down over 20% this week as of this writing on Friday,…\n","protected":false},"author":2,"featured_media":1832,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2239,272,277],"class_list":{"0":"post-1831","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-aggressive-competition","9":"tag-novo-nordisk","10":"tag-weight-loss-drugs"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/1831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=1831"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/1831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/1832"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=1831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=1831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=1831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}